Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D.
Yousef A, et al. Among authors: hurd mw.
NPJ Precis Oncol. 2024 Feb 3;8(1):27. doi: 10.1038/s41698-024-00505-0.
NPJ Precis Oncol. 2024.
PMID: 38310130
Free PMC article.